These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 10421234)

  • 1. Protective effect of an aldose reductase inhibitor against bone loss in galactose-fed rats: possible involvement of the polyol pathway in bone metabolism.
    Inaba M; Terada M; Nishizawa Y; Shioi A; Ishimura E; Otani S; Morii H
    Metabolism; 1999 Jul; 48(7):904-9. PubMed ID: 10421234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An aldose redutase inhibitor prevents the intimal thickening in coronary arteries of galactose-fed beagle dogs.
    Kasuya Y; Ito M; Nakamura J; Hamada Y; Nakayama M; Chaya S; Komori T; Naruse K; Nakashima E; Kato K; Koh N; Hotta N
    Diabetologia; 1999 Dec; 42(12):1404-9. PubMed ID: 10651257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of aldose reductase inhibitor on corneal epithelial barrier function in galactose-fed dogs.
    Kubo E; Mori K; Kobayashi T; Takahashi Y; Yokoi N; Kinoshita S; Kasahara T; Yonezawa H; Akagi Y
    J Ocul Pharmacol Ther; 1998 Apr; 14(2):181-90. PubMed ID: 9572544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation.
    He J; Gao HX; Yang N; Zhu XD; Sun RB; Xie Y; Zeng CH; Zhang JW; Wang JK; Ding F; Aa JY; Wang GJ
    Acta Pharmacol Sin; 2019 Jan; 40(1):86-97. PubMed ID: 29930278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Inhibition effect of epalrestat on rat lens osmotic expansion].
    Ji LX; Shen N; Li CN; Liu Q; Huan Y; Shen ZF
    Yao Xue Xue Bao; 2009 Oct; 44(10):1107-11. PubMed ID: 20055132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of an aldose reductase inhibitor (Epalrestat) on diabetic nephropathy in rats.
    Itagaki I; Shimizu K; Kamanaka Y; Ebata K; Kikkawa R; Haneda M; Shigeta Y
    Diabetes Res Clin Pract; 1994 Oct; 25(3):147-54. PubMed ID: 7851268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of aldose reductase inhibition with epalrestat on diabetes-induced changes in rat isolated atria.
    Booth RJ; Hodgson WC
    Clin Exp Pharmacol Physiol; 1993 Apr; 20(4):207-13. PubMed ID: 8485921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of epalrestat, an aldose reductase inhibitor, on the generation of oxygen-derived free radicals in neutrophils from streptozotocin-induced diabetic rats.
    Kashima K; Sato N; Sato K; Shimizu H; Mori M
    Endocrinology; 1998 Aug; 139(8):3404-8. PubMed ID: 9681489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of an aldose reductase inhibitor on glomerular basement membrane anionic sites in streptozotocin-induced diabetic rats.
    Isogai S; Inokuchi T; Ohe K
    Diabetes Res Clin Pract; 1995 Nov; 30(2):111-6. PubMed ID: 8833631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucose-induced hyperproliferation of cultured rat aortic smooth muscle cells through polyol pathway hyperactivity.
    Nakamura J; Kasuya Y; Hamada Y; Nakashima E; Naruse K; Yasuda Y; Kato K; Hotta N
    Diabetologia; 2001 Apr; 44(4):480-7. PubMed ID: 11357479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients.
    Hamada Y; Nakamura J; Naruse K; Komori T; Kato K; Kasuya Y; Nagai R; Horiuchi S; Hotta N
    Diabetes Care; 2000 Oct; 23(10):1539-44. PubMed ID: 11023149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldose reductase inhibitor improves insulin-mediated glucose uptake and prevents migration of human coronary artery smooth muscle cells induced by high glucose.
    Yasunari K; Kohno M; Kano H; Minami M; Yoshikawa J
    Hypertension; 2000 May; 35(5):1092-8. PubMed ID: 10818070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epalrestat, an Aldose Reductase Inhibitor, Restores Erectile Function in Streptozocin-induced Diabetic Rats.
    Yang BB; Hong ZW; Zhang Z; Yu W; Song T; Zhu LL; Jiang HS; Chen GT; Chen Y; Dai YT
    Int J Impot Res; 2019 Mar; 31(2):97-104. PubMed ID: 30214006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of an aldose reductase inhibitor on gastroenteropathy in streptozotocin-diabetic rats.
    Oya M; Hosokawa M; Tsukada H; Fukuda K; Nakamura H; Tsukiyama K; Nagashima K; Fujimoto S; Yamada Y; Seino Y
    Diabetes Res Clin Pract; 2003 Nov; 62(2):69-77. PubMed ID: 14581143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of aldose reductase inhibitor on microneurographically assessed peripheral sympathetic nerve activity in rats.
    Sato D; Kusunoki M; Shinzawa G; Feng Z; Nishina A; Nakamura T
    Auton Neurosci; 2015 Dec; 193():69-73. PubMed ID: 26272532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gedunin, A Neem Limonoid in Combination with Epalrestat Inhibits Cancer Hallmarks by Attenuating Aldose Reductase-Driven Oncogenic Signaling in SCC131 Oral Cancer Cells.
    Tanagala KKK; Baba AB; Kowshik J; Reddy GB; Nagini S
    Anticancer Agents Med Chem; 2018; 18(14):2042-2052. PubMed ID: 30062975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy.
    Hotta N; Kawamori R; Fukuda M; Shigeta Y;
    Diabet Med; 2012 Dec; 29(12):1529-33. PubMed ID: 22507139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polyol pathway and protein kinase C activity of rat Schwannoma cells.
    Kamiya H; Nakamura J; Hamada Y; Nakashima E; Naruse K; Kato K; Yasuda Y; Hotta N
    Diabetes Metab Res Rev; 2003; 19(2):131-9. PubMed ID: 12673781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alteration of urinary sorbitol excretion in WBN-kob diabetic rats - treatment with an aldose reductase inhibitor.
    Tsugawa T; Shinohara R; Nagasaka A; Nakano I; Takeda F; Nagata M; Oda N; Sawai Y; Hayakawa N; Suzuki A; Itoh M
    J Endocrinol; 2004 Jun; 181(3):429-35. PubMed ID: 15171691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of new epalrestat analogues as aldose reductase inhibitors (ARIs).
    Reddy TN; Ravinder M; Bagul P; Ravikanti K; Bagul C; Nanubolu JB; Srinivas K; Banerjee SK; Rao VJ
    Eur J Med Chem; 2014 Jan; 71():53-66. PubMed ID: 24275248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.